Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotype

PLoS ONE

Volumn 3, Issue 6, 2008, Pages

  Abdoul, Hendy ^a   Mallet, Vincent ^b   Pol, Stanislas ^b   Fontanet, Arnaud ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS C ANTIBODY; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD; BLOOD; GENETICS; VIROLOGY;

HEPATITIS C VIRUS;

ALPHA-FETOPROTEINS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 48649099540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002391     Document Type: Article

References (12)

1. Halbrecht I, Klibanski C (1956) Identification of a new normal embryonic haemoglobin. Nature 178: 794-5.
2. Gupta S, Bent S, Kohlwes J (2003) Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 139: 46-50.
3. Taketa K (1990) Alfafetoprotein: reevaluation in hepatology. Hepatology 12: 1420-32.
4. Males S, Raafat Gad R, Esmat G, Abobakr H, Anwar M, et al. (2007) Serum alpha foetoprotein level predicts treatment outcome in chronic hepatitis C. Antiviral Therapy 12: 797-803.
5. Bedossa P, Poynard T (1996) An algorithm for grading of activity in chronic hepatitis C. Hepatology 24: 289-93.
6. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, et al. (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37: 600-9.
7. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J (2000) Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 31: 211-8.
8. Germain L, Noel M, Gourdeau H, Marceau N (1988) Promotion of growth and differentiation of rat ductular oval cells in primary culture. Cancer Res 48: 368-78.
9. Shiojiri N, Lemire JM, Fausto N (1991) Cell lineages and oval cell progenitors in rat liver development. Cancer Res 51: 2611-20.
10. Dabeva MD, Shafritz DA (1993) Activation, proliferation, and differentiation of progenitor cells into hepatocytes in the D-galactosamine model of liver regeneration. Am J Pathol 143: 1606-20.
11. Tsamandas AC, Syrokosta I, Thomopoulos K, Zolota V, Dimitropoulou D, et al. (2006) Potential role of hepatic progenitor cells expression in cases of chronic hepatitis C and their relation to response to therapy: a clinicopathologic study. Liver Int 26: 817-26.
12. Yin L, Lynch D, Ilic Z, Sell S (2002) Proliferation and differentiation of ductular progenitor cells and littoral cells during the regeneration of the rat liver to CCl4/2-AAF injury. Histol Histopathol 17: 65-81.